CreoSG Absorbs ImmunoVaxBio... "Accelerating New Drug Pipeline Development Led by Listed Companies"

CreoESG is undertaking a governance restructuring to accelerate the development of its new drug pipeline. On the 27th, CreoESG announced that it has decided to merge its subsidiary ImmunoVaxBio through an absorption-type merger. The merger ratio between the two companies is 1 to 0.6997717, and the merger date is set for August 30.

CreoESG plans to actively continue investing in new drug development following the subsidiary merger, intensifying efforts toward commercialization. Through this merger, ImmunoVaxBio’s universal vaccine platform ‘SUV-MAP’ and its vaccine pipeline, including the AIDS vaccine, will be internalized.

A CreoESG official stated, “We judged that the results of the pipeline held by ImmunoVaxBio are becoming visible, so we decided on this merger to internalize it and have the listed company CreoESG take the lead in new drug development.” He added, “We plan to employ various strategies such as accelerating the development of existing pipelines, joint new drug development cooperation between listed companies, and pipeline expansion.”

ImmunoVaxBio, in collaboration with the UN-affiliated international organization ‘International Vaccine Institute (IVI),’ has developed various vaccines and secured related technologies, recently launching the vaccine development platform SUV-MAP. SUV-MAP features its proprietary VSV vector technology, which maximizes safety and immune response during the vaccine candidate development process. Using SUV-MAP, a vaccine candidate can be confirmed within five months after development initiation.

CreoESG plans to accelerate the development of the world’s first AIDS vaccine ‘SAV001’ through the merger. For the U.S. Phase 2 clinical trial of SAV001, sample production is underway with a global Contract Development and Manufacturing Organization (CDMO). The company explained that rapid progression to Phase 2 clinical trials is possible because, in the past U.S. Phase 1 trial, antibody levels increased up to 512-fold, neutralizing antibodies were formed, and the vaccine’s critical ability to respond to variants was confirmed.

A company representative emphasized, “ImmunoVaxBio has been recognized for its vaccine development technology and continues to collaborate with IVI.” He added, “Through the synergy between CreoESG’s domestic and international bio company networks, investment capabilities, and vaccine development technology, we will strengthen competitiveness in the global vaccine market.”